Invasive candidiasis is a bloodstream and deep-tissue infection caused by fungi of the genus Candida, affecting roughly 2 to 10 percent of patients in intensive care units and carrying mortality rates that can exceed 40 percent in vulnerable groups.1PubMed Central. Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives Unlike superficial yeast infections that stay on the skin or mucous membranes, invasive candidiasis means the fungus has entered the bloodstream or seeded internal organs. The condition is almost exclusively a hospital-acquired problem, and despite decades of research, diagnosing it quickly remains one of the hardest challenges in infectious disease medicine.
How Candida Goes From Harmless Colonizer to Lethal Invader
Most people carry Candida albicans in their gut without ever knowing it. The fungus lives quietly alongside billions of bacteria, kept in check by an intact intestinal lining and a healthy immune system. The trouble starts when those defenses break down. Broad-spectrum antibiotics, for instance, can wipe out the bacterial competition that normally limits Candida growth, allowing the yeast to expand dramatically in the gastrointestinal tract.2PubMed Central. Candida albicans as Marker of the Impact of Antibiotics on Gut Microbiome That overgrowth alone does not cause invasive disease, but it sets the stage.
For Candida to actually cross the intestinal wall, the fungus typically switches from its round yeast form to elongated filaments called hyphae. These hyphae physically push into the cells lining the gut. A key weapon in this process is candidalysin, a toxin encoded by the ECE1 gene, which damages and kills the epithelial cells it encounters. Researchers have shown that candidalysin-driven damage is a major route for the fungus to punch through the gut lining.3PubMed Central. From intestinal colonization to systemic infections: Candida albicans translocation and dissemination – Section: Translocation across the intestinal epithelium Even strains engineered to lack candidalysin can still cross at low levels, though, suggesting that the fungus has additional tricks researchers have not fully identified.4PLOS Pathogens. Candida albicans translocation through the intestinal epithelial barrier is promoted by fungal zinc acquisition and limited by NFκB-mediated barrier protection
An interesting wrinkle is that the round yeast cells themselves can hitch a ride. When hyphae bore through and damage the intestinal barrier, yeast cells passively slip through the openings. If the barrier is disrupted by some other insult, such as a toxin or severe inflammation, yeast cells can cross even without any hyphae present, as long as barrier integrity is sufficiently compromised.5PubMed Central. Fungal determinants contributing to translocation of Candida albicans yeast cells through the intestinal epithelial barrier This matters clinically because it means gut translocation is not a single, predictable event. It can happen through multiple pathways depending on the patient’s condition.
The gut is not the only entry point. Central venous catheters are a major portal. Candida species readily form biofilms on catheter surfaces, embedding themselves in a protective matrix that shields them from both the immune system and antifungal drugs. Over 90 percent of catheter-related Candida bloodstream infections involve central venous catheters rather than peripheral lines.6PubMed Central. Biofilm: The invisible culprit in catheter-induced candidemia This is why catheter removal is often the first step in treatment.
Who Is Most at Risk
Invasive candidiasis is overwhelmingly a disease of hospitalized, critically ill people. A systematic review and meta-analysis of risk factors in ICU patients found that the strongest predictors were broad-spectrum antibiotic use (roughly a fivefold increase in odds), blood transfusion, existing Candida colonization, central venous catheters, and total parenteral nutrition, each carrying odds ratios between about 4.6 and 5.6.7PubMed Central. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis Those numbers reflect how many of these factors tend to cluster in the same patient: someone on a ventilator, receiving IV nutrition through a central line, and on multiple antibiotics is simultaneously accumulating several independent risks.
Recent surgery is another common thread, particularly abdominal surgery where the gut barrier is physically disrupted. Data from a randomized clinical trial confirmed that recent surgery was more common among ICU patients with invasive candidiasis, while classic risk factors like neutropenia and cancer were proportionally more common among non-ICU patients with the disease.8PubMed. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial In other words, the ICU version of the disease and the oncology-ward version often have different profiles, even though they share the same fungus.
Neutrophils, the white blood cells that serve as the immune system’s rapid-response team, are critical for keeping Candida in check. Patients whose neutrophil counts are severely depleted, whether from chemotherapy, bone marrow failure, or rare genetic conditions, are at particular risk for deep-tissue forms of the disease. Studies in animal models and observations in patients with immune deficiencies have consistently shown that neutrophil function is the single most important immune factor in preventing fungal invasion from becoming overwhelming.9PubMed Central. The role of neutrophils in host defense against invasive fungal infections
The Species Are Shifting
For decades, Candida albicans was the dominant cause of invasive candidiasis, and it still gets the most attention. But the landscape has changed. In the United States, C. albicans now accounts for fewer than half of all candidemia isolates. The biggest proportional increase has been in C. glabrata, which makes up a third or more of U.S. cases, followed by C. parapsilosis at roughly 15 percent.10Journal of Antimicrobial Chemotherapy. Changes in the epidemiological landscape of invasive candidiasis In some regions, the shift is even more dramatic. An Indonesian teaching hospital reported that non-albicans species caused over three-quarters of candidemia cases over an 11.5-year observation period, with C. parapsilosis alone responsible for more than a third.11PubMed Central. CHANGING PATTERN OF NON ALBICANS CANDIDEMIA: OCCURENCE AND SUSCEPTIBILITY PROFILE IN AN INDONESIAN SECONDARY TEACHING HOSPITAL
This species shift matters because non-albicans species often have reduced susceptibility to fluconazole, the azole antifungal that was long the workhorse of candidemia treatment. The rise of these species has tracked alongside increasing fluconazole use, suggesting a classic selection pressure dynamic.12PubMed. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia A hospital that still assumes most candidemia is C. albicans and reaches for fluconazole first may be starting treatment with a drug that does not cover the actual pathogen.
The Candida auris Problem
No discussion of the shifting species landscape is complete without Candida auris, which has emerged as a serious hospital infection control threat. Unlike most Candida species, C. auris spreads efficiently between patients and persists on hospital surfaces for weeks. It frequently resists multiple drug classes simultaneously. Azole resistance in C. auris can arise from mutations in the drug target gene ERG11 and from overexpression of efflux pumps that actively pump the drug out of the fungal cell.13PubMed Central. Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris Additional resistance mechanisms involve gain-of-function mutations in the transcription factors that control those pumps.14PubMed Central. Exploration of novel mechanisms of azole resistance in Candida auris Its hospital transmission dynamics and environmental persistence have made it a focus of infection control programs worldwide.15PubMed Central. The rising challenge of Candida auris: insights into its transmission, drug resistance, and infection control strategies
Why Diagnosis Takes Too Long
Blood culture is still considered the standard method for detecting Candida in the bloodstream, but it has serious limitations. It misses a substantial fraction of cases because the fungus is often present at very low concentrations in the blood, and even when positive, results take days to come back. That delay matters because mortality climbs the longer appropriate antifungal therapy is withheld.16PubMed Central. Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives
Biomarker-based tests aim to fill this gap. The most studied is beta-D-glucan (BDG), a component of the fungal cell wall that can be detected in the blood. In newborns, a meta-analysis found that at a cutoff of 80 pg/mL, the test had about 89 percent sensitivity, making it potentially useful for ruling out neonatal invasive candidiasis when the result is negative. Specificity, however, was only around 60 percent at that threshold, meaning many positive results are false alarms.17PubMed. Diagnostic accuracy of serum (1,3)-beta-d-glucan for neonatal invasive candidiasis: systematic review and meta-analysis In adult ICU patients, the picture is less encouraging. A prospective study found that initial BDG testing had about 74 percent sensitivity and only 45 percent specificity for invasive candidiasis, and serial testing did not substantially improve those numbers.18PubMed Central. The added value of (1,3)-β-D-glucan for the diagnosis of Invasive Candidiasis in ICU patients: a prospective cohort study BDG remains a useful piece of the diagnostic puzzle, but it is not the rapid, definitive test clinicians wish they had.
Deep-organ involvement makes diagnosis even harder. Hepatic candidiasis, for example, typically appears in patients recovering from prolonged neutropenia. Imaging with CT or PET scans can identify characteristic lesions in the liver and spleen, but by the time those lesions are visible, the disease is already advanced.19PubMed Central. Hepatic Candidiasis in a Non-neutropenic Patient In many patients with deep-tissue candidiasis, blood cultures are negative even though the fungus is actively causing organ damage.
Treatment and Why Echinocandins Come First
Echinocandins, a class that includes caspofungin, micafungin, and anidulafungin, are the preferred first-line treatment for invasive candidiasis. They work by blocking an enzyme called glucan synthase, which builds a critical structural component of the fungal cell wall. Without that scaffold, the cell wall weakens and the fungus dies from what is essentially an inability to hold itself together.20PubMed Central. Echinocandins – structure, mechanism of action and use in antifungal therapy Because human cells do not have cell walls, echinocandins are generally well tolerated with few side effects.
A network meta-analysis pooling data from over 2,400 patients across multiple randomized trials found that echinocandins had the highest treatment success rate for all forms of invasive candidiasis, outperforming both amphotericin B and the triazole antifungals. Rank probability analysis favored echinocandins as the most effective choice 98 percent of the time.21PubMed. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis That advantage, combined with their safety profile, explains why guidelines now recommend echinocandins as initial therapy for most patients with candidemia, with a switch to oral fluconazole considered once the patient has improved and the infecting species is confirmed to be susceptible.
The Resistance Threat
Echinocandin resistance is still uncommon overall, but it is rising in certain species. C. glabrata (now also classified as Nakaseomyces glabratus) is the species of greatest concern. Resistance develops through mutations in the FKS genes, which encode the glucan synthase enzyme that echinocandins target. A study screening over a thousand C. glabrata isolates found 51 with FKS hotspot mutations, and virtually all of these were resistant to at least one echinocandin by laboratory testing.22PubMed Central. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance Recent genomic work has revealed that C. glabrata can even swap genetic material between its FKS1 and FKS2 genes, creating novel chimeric sequences that confer resistance through a mechanism that was not previously recognized.23npj Antimicrobial Agents and Resistance. Hotspot gene conversion between FKS1 and FKS2 in echinocandin resistant Candida glabrata serial isolates
C. auris presents a similar concern. Echinocandin-resistant C. auris isolates also carry FKS1 mutations, and genomic analysis suggests that resistance develops in a stepwise fashion: initial cell wall stress responses, followed by drug adaptation, and finally the specific hotspot mutations that fully block echinocandin activity.24PubMed Central. Evolutionary accumulation of FKS1 mutations from clinical echinocandin-resistant Candida auris Because C. auris often arrives already resistant to azoles, echinocandin resistance in this species can leave physicians with very few options. That combination of multi-class resistance and hospital transmissibility is what makes C. auris such an alarming pathogen.
New Drugs on the Horizon
The antifungal pipeline has been unusually active in recent years, with three agents attracting the most attention for invasive candidiasis. Rezafungin is a next-generation echinocandin with an unusually long half-life, allowing once-weekly dosing instead of the daily infusions required by older echinocandins. That dosing schedule makes it attractive for outpatient treatment programs where patients can come in weekly rather than staying in the hospital for daily IV therapy.25PubMed Central. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action
Ibrexafungerp works on the same fungal target as echinocandins (glucan synthase) but belongs to a different chemical class and is available as an oral pill. It has shown activity against fluconazole-resistant and echinocandin-resistant Candida species, which means it could serve as a step-down option after initial IV therapy or as an alternative when standard echinocandins fail.26PubMed Central. The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis Fosmanogepix works through an entirely different mechanism, interfering with an enzyme involved in attaching proteins to the fungal cell surface. Because its target is unrelated to those of echinocandins or azoles, it retains activity against multi-drug-resistant species including C. auris.27PubMed. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix
Invasive Candidiasis in Premature Infants
Extremely premature newborns occupy a particularly fragile niche. A multicenter study from the Netherlands and Belgium found invasive candidiasis in about 0.8 percent of infants born before 30 weeks of gestation. While that percentage sounds small, the affected babies were profoundly vulnerable: born at an average gestational age of about 25.7 weeks with birth weights averaging around 827 grams. Nearly half had already experienced sepsis or gastrointestinal disease before the Candida infection appeared, and C. albicans was the causative species in 83 percent of cases. The disease course was severe, with a third developing disseminated organ involvement and the majority requiring invasive ventilation or blood transfusions. Antifungal treatment was delayed in over half of the cases, underscoring how difficult early recognition remains even in a closely monitored NICU population.
The Financial Weight of the Disease
Beyond the clinical toll, invasive candidiasis is enormously expensive to treat. A systematic review of economic studies found that the mean total cost per patient ranged from about $48,000 to over $157,000, with hospitalization accounting for more than half of that spending. The cost per hospitalization alone ranged from roughly $10,000 to $38,000, depending on the study and healthcare system. All of the data came from developed Western countries, and none captured indirect costs like lost productivity. The real global burden is certainly higher than these figures suggest.
Antifungal stewardship, the systematic effort to optimize how antifungal drugs are prescribed, has emerged as one strategy to curb both costs and resistance. While antimicrobial stewardship programs have been established for decades in the antibacterial space, antifungal stewardship has received less attention and comes with unique challenges. The complexity of fungal infections, the difficulty of definitive diagnosis, and the limited number of drug classes all make antifungal prescribing decisions harder to standardize than antibiotic ones.28PubMed Central. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium Still, the principles are the same: ensuring the right drug reaches the right patient at the right time, while avoiding unnecessary use that drives resistance.
Why Antifungal Stewardship Faces Unique Obstacles
Antibacterial stewardship benefits from rapid diagnostics that can identify bacteria and their resistance patterns within hours. Fungal diagnostics lag far behind. As covered above, blood cultures for Candida can take days and miss many cases entirely. That diagnostic gap forces clinicians into an uncomfortable choice: start empiric antifungal therapy on suspicion alone, potentially overtreating many patients who do not have a fungal infection, or wait for confirmation and risk losing time in patients who do. Either path has real consequences. Empiric overuse contributes to resistance and adds unnecessary drug costs. Delayed treatment raises mortality.
The limited number of antifungal drug classes compounds the problem. Whereas antibacterial medicine has dozens of drug families to rotate through, clinicians treating invasive Candida infections rely mainly on three: echinocandins, azoles, and amphotericin B. Losing any one of those to widespread resistance would be devastating. This scarcity is why the pipeline agents discussed earlier carry so much weight. Each new mechanism of action adds breathing room, giving clinicians alternatives when existing drugs fail and reducing the selective pressure on any single class.
Another complicating factor is the biology of Candida biofilms. When the fungus colonizes a catheter or a prosthetic device, it embeds itself in an extracellular matrix that can increase the drug concentration needed to kill it by orders of magnitude compared to free-floating cells.29PubMed Central. Biofilm: The invisible culprit in catheter-induced candidemia This is why removing the infected device, not just adding more drug, is usually essential. A stewardship program that focuses only on drug selection without addressing device management misses a critical piece of the puzzle.